BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys.
The lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. The Phase III Confirmatory Study is expected to be completed by the first quarter of 2016, with top-line data expected to be available in the middle of 2016.
KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase II clinical study is expected to be filed with the U.S. Food and Drug Administration in the first half of 2016.
In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway. The Company intends to meet with regulatory authorities in 2016 to present its clinical development plan for Shigamab™ in the treatment of sHUS.
BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.